Side-by-side · Research reference

AOD-9604vsP21

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BAnimal-MechanisticHUMAN-REVIEWED8/36 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

P21

CNTF-Derived Neuropeptide · Animal Model Evidence

CNTFR/gp130Primary receptorGuo 2022

Animal onlyEvidence level

NeurogenesisPrimary effectJia 2020 Mottolese 2024

SQ · Site unspecified · Frequency unknown

01Mechanism of Action

Parameter

AOD-9604

P21

Primary target

β3-adrenergic receptor (proposed)Ng 2000

CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders

Feedback intact?

No GH-axis or IGF-1 feedback

—

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

P21

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

—

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

Animal models only

CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024 Cox 2026 Jia 2020

Duration

8–12 weeks per cycle

Not specified

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Human dosing

—

No established protocol

No clinical trial data available.

Animal models (mice)

—

Dose and route not specified in abstractsMottolese 2024 Jia 2020

In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.

Route

—

Presumed subcutaneous or intraperitoneal (animal studies)

04Side Effects & Safety

Parameter

AOD-9604

P21

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Human safety data

—

None available

No clinical trials in humans.

Animal tolerability

—

Well-tolerated in mouse models; no toxicity reported in available abstracts

Theoretical risks

—

Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

P21

·Use in humans not validated

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

P21

·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
·Pregnancy or lactation (no safety data)

05Administration Protocol

Parameter

AOD-9604

P21

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Not established. No FDA approval, no clinical trial data.

2. Injection site

SQ — abdomen preferred. Rotate sites.

In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

—

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

—

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

P21

— no documented stacks